Hormone Replacement Therapy Market will be USD 25.09 Billion, Propelled by Increasing Awareness of Postmenopausal Issues among Women, and Hormonal Imbalance Disorders with the Rising Geriatric Population
24 Jan, 2023

According to Renub Research's latest report, "Hormone Replacement Therapy Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" the Hormone Replacement Therapy Market is estimated to reach US$ 25.09 Billion by 2027. Hormone replacement therapy is a treatment that includes the management of low levels of hormones resulting from a lack of secretion in the human body. It is acceptable for elderly patients suffering from hypogonadism, women in menopausal transition, and patients with a deficiency of growth hormone. The main benefit of Harmon Replacement Therapy is that it helps relieve most menopausal symptoms, such as hot flashes, night sweats, mood swings, etc. HRT use is highest in the UK, France, and Germany and lowest in Spain. HRT is more commonly specified in aged women. As per the National Institute for Health and Care Excellence, in April 2022, about a Million women in the United Kingdom use treatment for the symptoms of menopause, although access to HRT has been described as a "postcode lottery."

Hormone replacement therapy primarily focuses on replacing the estrogen that the body no longer makes after menopause. There are two main types of hormone replacement therapy: estrogen and progesterone. Estrogen therapies are numerous and include those indigenous to the human ovary. In contrast, progesterone used to have progesterone made by the human ovary and progesterone-like substances, also known as progestins. Furthermore, it treats cancers that use hormones to grow, such as prostate and breast cancers. 

Hormone therapy is also called hormone treatment, hormonal therapy, or endocrine therapy. HRT starts as soon experiences menopausal symptoms and will not usually need to have any tests first. However, a blood test to measure hormone levels may be carried out between the ages of 40 to 45. Blood tests may also be carried out to help diagnose suspected premature menopause under 40 and menopausal symptoms.

However, Tablets are 1 of the most common forms of HRT. They are usually taken once a day. Both estrogen-only and combined HRT is available as tablets. The primary prime drivers of the hormone replacement therapy Industry are expanded interest in regenerative prescriptions, for example, against maturing and conceptive cycle-supporting therapy like menopausal hormone replacement. Therefore, sales of hormone replacement therapy products through hospital pharmacies and retail pharmacies are likely to be on an upswing, with developers relying on these channels than online selling. 

Additionally, based on evidence, most advisory bodies have recommended the use of HRT as a first-line therapeutic intervention for the prevention and treatment of osteoporosis for all women with POI, as well as in postmenopausal women under the age of 60, in particular those with menopausal symptoms.

Estrogen dominates the market share during the forecast period.

Estrogen therapy is a form of hormone replacement therapy generally used to manage and treat menopausal symptoms, especially vasomotor symptoms and urogenital atrophy, which is often associated with a significantly decreased quality of life. It has also proved beneficial in a patient with an increased risk of osteoporotic fractures with long-term use.

One important function of estrogen replacement therapy is its influence on the acid pH in the vaginal canal. Estrogen plays a very important role in many body functions, that's including bone-building, thickens, preventing osteoporosis, etc. According to the Renub Research Report, the demand for estrogen hormone replacement therapy is expected to grow on the back of the growing menopausal rate worldwide. The sales of estrogen hormone replacement therapy are likely to surpass US$ 11,083.7 Million by 2027, higher than those of other products, including thyroid and human growth, testosterone, and progestogen. In Latin America, the demand for estrogen replacement is anticipated to be driven by the wide range of target population bases across the region's nations.

Menopause will capture maximum market

Menopause hormone therapy (M is the most efficient treatment for symptoms of the acute climacteric syndrome and efficient prevention of long-term estrogen deficiency. Lower hormone levels may lead to symptoms like hot flashes, night sweats, vaginal dryness, and thin bones. In the United States, approximately 1.3 million women become menopausal each year. It typically begins between the ages of 51 and 52. Also, over 2 million US women enter menopause annually, and more than 6 million women worldwide. 

Menopausal hormone replacement therapy should be begun when problems due to menopausal symptoms appear and the pH of the vaginal lumen in the years preceding menopause typically ranges between 4.5 and 6.0, as it varies relative to the menstrual cycle. 

For most women, menopause is marked by the end of monthly menstruation due to loss of ovarian follicular function. The hormonal changes associated with menopause can affect mental, emotional, physical, and social well-being. In addition, the symptoms experienced during and following the menopausal transition vary substantially from person to person. 

The effective recommendation for the duration of menopausal hormone therapy (MHT) use has been five years (and not beyond age 60 years). However, for most women, hot flashes persist for as long as 10 to 20 years after the final menstrual period.

Parenteral holdsthe largest market share

Parenteral estrogen therapy protects against the effects of andropause (similar to female menopause), which are convinced by conventional androgen suppression and include osteoporotic fracture, hot flashes, asthenia, and cognitive dysfunction. In addition, parenteral estrogen therapy is significantly cheaper than current endocrine therapy, with substantive economic implications for health providers.

North America remains the main region for Harmon Replacement market.

Major factors include medicine movement structures, improvement of new subtleties, and rising objective people inside North America. Furthermore, in Mexico, the rising population base and surge in healthcare spending have significantly supported the growth of the hormone replacement therapy market. Moreover, universal healthcare coverage is considered among the most comprehensive health schemes transforming the country's healthcare infrastructure.

Competitive Landscape:-

Harmon Replacement Therapy Market is divided into Merck KgaA, Bayer AG, Pfizer Inc., Abbott Laboratories, Novartis AG, Novo Nordisk A/S, Amgen, Inc., F. Hoffmann-La Roche, and Eli Lilly and Company.

Market Summary:-

• Type: - The Report covers the Harmon Replacement Therapy Market by Type in 5 viewpoints (Estrogen, Progesterone, Human Growth, Thyroid, and Testosterone)
• Disease Type: - The Report covers the Harmon Replacement Therapy Market by Disease Type in 5viewpoints (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Others)
• Route of Administration: - The Report covers the Harmon Replacement Therapy Market by Route of Administration Type in 4 viewpoints (Oral, Parenteral, Transdermal, and Others)
• Region:- The Report covers the Harmon Replacement Therapy Market by region in 5 viewpoints(North America, Europe, Asia Pacific, South America, and Middle East & Africa)